Join us for an informative webinar focused on metastatic lobular breast cancer (mILC). In this session, Dr. Sherry Shen, a breast medical oncologist at MSK, will provide insights into the unique challenges of mILC, explain how it differs from other types of breast cancer, and discuss the latest advancements in treatment. This is a great opportunity to deepen your understanding to make informed decisions, and have your questions answered by an expert.
Webinar Highlights:
- mILC is Different: Invasive lobular carcinoma (mILC) has distinct biological characteristics compared to other breast cancers.
- Genetic Testing Matters: Testing the tumor tissue or blood for genetic changes is important. It can help guide treatment decisions and point to clinical trials or targeted therapies that may work better for your type of cancer.
- Monitoring with ctDNA: A blood test called circulating tumor DNA (ctDNA) is a new tool doctors are using to track how well treatments are working and if the cancer is changing over time.
- What’s New in Treatment for HR+ MBC:
- Camizestrant – A new oral hormone therapy being tested for cancer with an ESR1 mutation.
- Inavolisib – a treatment that targets specific gene mutations (like PIK3CA) to help hormone therapy work better.
- Clinical Trials to Know About:
- Lenvatinib + Pembrolizumab
- REPLOT
- ELAINE-3
